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Abstract 
Immunochemotherapy adverse events affecting the 
gastrointestinal tract usually consist of self-limiting nausea/ 
vomiting or diarrhoea, while bleeding and perforation are 
rare. A 42-year-old woman treated with bendamustine/ 
rituximab for splenic marginal zone lymphoma developed a 
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life-threatening protein-losing enteropathy that was a 
diagnosis conundrum, ranging from drug-induced, immune- 
mediated, neoplastic and infectious forms. Suspecting 
opportunistic viral infection but with unremarkable 
immunohistochemistry and peripheral blood tests, the 
diagnosis of Human Cytomegalovirus enteritis was made 
only by means of quantitative real-time polymerase chain 
reaction carried out on mucosal specimens. Steroid discon-
tinuation and a prolonged course of antiviral therapy  
allowed the patient to overcome the critical phase and to 
achieve gradual normalisation of stool frequency, body 
mass index, laboratory tests lasting one year, while 
disappearance of mucosal viral load resulted soon evident. 
Human Cytom-egalovirus end-organ disease localised at the 
gastrointestinal tract is a serious condition whose prompt 
diagnosis and treatment prevents poor patients prognosis. 
  
Keywords: Human Cytomegalovirus; Immunochemo-
therapy; Mucosal viral load; Protein-losing enteropathy 
 
Abbreviations: EBV: Epstein Barr Virus; HCMV: 
Human Cytomegalovirus; SMZL: Splenic Marginal Zone 




Human Cytomegalovirus (HCMV), a member of the 
Herpesviridae family, usually establishes lifelong latency in 
target cells and reactivates in the event of reduced host 
immunity, giving rise to serious systemic or end-organ 
disease [1]. In the latter condition, diagnosis is challenging 
because viral DNA is barely detectable in peripheral blood, 
and the methods applied on tissue samples may miss virus 
detection. With regard to the gastrointestinal tract, it is 
widely accepted that immunohistochemistry is the best 
technique to confirm or rule out HCMV infection [2]. 
Moreover, the search for circulating class M HCMV-
specific antibodies is considered unreliable in 
immunocompromised patients, who may not mount a proper 
immunoglobulin response [3]. In this scenario, the 
possibility of detecting viral DNA on tissue samples of the 
target organ by quantitative real-time polymerase chain 
reaction (qPCR) is of meaningful clinical value since it 
provides an accurate qualitative and quantitative assessment 
of viral load, thus facilitating appropriate patient 
management [4]. Here, we describe the case of a patient who 
underwent upfront immunochemotherapy for non-Hodgkin 
lymphoma and developed a life-threatening malabsorption 
syndrome, whose cause was a diagnostic conundrum. 
 
2. Methods 
2.1 Mucosal samples 
Fresh perendoscopic distal ileum and colonic mucosal 
biopsies were collected from both macroscopically normal 
and diseased areas in order to perform immune-
histochemistry, in situ hybridisation and quantitative real-
time polymerase chain reaction assays. After harvesting, 
two mucosal specimens from each area were immediately 
fixed in 10% neutral buffered formalin for traditional 
immunohistochemistry and in situ hybridisation, while two 
biopsies were snap-frozen and cryopreserved until use for 
the measurement of viral DNA load. 
 
2.2 Histology and immunohistochemistry 
Formalin-fixed mucosal specimens were paraffin embedded 
to undergo sectioning of slices of 3 μm thickness, and then 
transferred to pre-treated glass slides. The haematoxylin-
eosin staining was performed following standard protocol. 
Specific immunostaining for HCMV was carried out on 
seriate sections with monoclonal mouse anti-HCMV 
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antibodies (clones CCH2 and DDG9 that recognise HCMV 
immediate-early and early antigens, respectively; 1:5 
dilution; DAKO, Denmark - Code M0854). All samples 
were processed using a sensitive “Bond polymer Refine” 
detection system in an automated Bond immunohisto-
chemistry instrument (Leica Biosystems, Germany). 
Appropriate positive controls were used, and positive cells 
were evaluated by an expert Pathologist. 
 
2.3 In situ hybridisation 
Three μm-thick slices of paraffin-embedded tissue were 
transferred to pretreated glass slides and were processed 
using an automated in situ Hybridisation Kit Protocol 
(EBER probe PB0589) with Leica BOND-MAX system 
and Leica BOND-III system (Leica Biosystems) for Epstein-
Barr virus (EBV) detection. 
 
2.4 Quantitation of viral DNA load 
HCMV and EBV DNA loads were assessed on both freshly 
collected whole peripheral blood samples and endoscopic 
specimens by quantitative real-time polymerase chain 
reaction as previously reported [5]. Results were expressed 
in terms of copies/ml of blood and copies/105 cells for 
mucosal samples, as appropriate. Normalisation of viral 
DNA load in tissue samples was obtained by the parallel 
quantitative determination of the β2-microglobulin house-
keeping gene. The lower limit of detection is 1 DNA input 
target DNA copies [5]. 
 
3. Case Report 
A 42-year-old Caucasian woman with splenic marginal 
zone lymphoma (SMZL) was admitted to the Internal 
Medicine Unit of A.O.U.I. Policlinico Rossi (Verona, 
Italy) because of severe dehydration and hypokalaemia due 
to watery diarrhoea, nausea, abdominal cramps, fever, 
asthenia, peripheral oedema and weight loss (15% of body 
weight in two weeks). SMZL had been diagnosed two 
months earlier during hospitalisation for Herpes Zoster 
virus infection of the genital area, when she was also 
complaining of fatigue due to pancytopenia and pain in the 
upper left abdominal region due to marked splenomegaly. 
According to the SMZL prognostic index [6] she was 
considered a high risk SMZL-IIL case and was offered to 
undergo splenectomy (declined) or immunochemotherapy 
with rituximab/bendamustine. Ten days after starting this 
treatment, she developed nausea and diarrhoea, so a course of 
empirical cephalosporine therapy was initiated in the 
suspicion of an intercurrent infection. Due to worsening of 
symptoms, the patient was then admitted to the Internal 
Medicine Unit with severe hypokalaemia (2.2 mmol/L, 
normal range: 3.40-4.80) causing electrocardiographic 
alterations, elevated International Normalised Ratio (3.49, 
normal range: 0.80-1.17), hypoproteinaemia (30 g/L, 
normal range: 60.0-83.0), and hypotransferrinaemia (0.6 
g/L, normal range: 2.00-3.60), as hallmarks of severe 
dehydration and malnutrition.  
 
Since proteinuria was ruled out, lymphoma progression was 
first hypothesised as the cause of the protein-losing 
enteropathy. However, the abdominal ultrasound scan 
showed a critical reduction of the splenomegaly (pole-polar 
axis from 20 to 14 cm) and bone marrow biopsy revealed 
clearance of the pathological cell clones. In the meanwhile, 
all the cultures, molecular biology and serology 
microbiological investigations carried out on both stool and 
blood samples were negative. Moreover, coeliac serology 
with search for anti-tissue transglutaminase class A and G 
antibodies turned out to be negative, although the levels of 
both A and G immunoglobulin classes were low, whereas 
the faecal occult blood test was positive and faecal 
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calprotectin was high (993 /g, normal value <100). From a 
therapeutic point of view, the patient did not improve 
despite total parenteral nutrition, albumin and electrolyte 
supple-mentation, steroid therapy (methylprednisolone 40 
mg/day i.v.), as well as administration of immunoglobulins 
(0.4 g/kg i.v. on five consecutive days).  
 
Following a multidisciplinary evaluation with both a 
Haematologist and a Gastroenterologist, the differential 
diagnosis between drug-induced enteropathy, immuno-
deficiency enteropathy and opportunistic viral enteritis was 
proposed. The patient therefore underwent gastroscopy and 
colonoscopy, both showing  macroscopically normal mucosa 
with unremarkable histological examination, whereas the 
magnetic resonance enterography showed ileal loops with 
thickened walls and parietal contrast enhancement (Figure 
1A). A wireless capsule endoscopy was then carried out that 
revealed large ulcerated areas surrounded by intensely 
congested and erythematous mucosa at the distal ileum. This 
finding directed the diagnosis towards viral enteritis since 
ulcerative lesions are rare in both drug-induced and 
immunodeficiency enteropathies. A second lower endo-
scopy reaching the distal ileum was then performed, with 
mucosal sampling of the damaged (Figure 1B) and not-
damaged areas for both traditional histology and viral load 
assessment. The immunohistochemistry and in situ hybrid-
disation (see Supplementary material) ruled out lymphoma 
and HCMV or EBV infection (Figure 1C).  
EBV-DNA in peripheral blood was also undetectable, 
whereas HCMV-DNA turned out to be positive (251 
IU/mL). This was mirrored by a high HCMV load in the 
mucosa of the distal ileum (2,328 copies/105 cells) as 
assessed by qRT-PCR, whilst only a few copies of EBV-
DNA were detected  (23 copies/105 cells). The diagnosis of 
HCMV-enteritis was therefore confirmed and the patient 
underwent quick tapering of the steroid, while a course of 
antiviral therapy with ganciclovir (5 mg/kg bid i.v.) was 
undertaken for an extended period of four weeks 
considering her profound immunosuppression due to both 
immunochemotherapy and severe malnutrition. This led to 
significant improvement of the patient's clinical condition, 
with normalisation of stool frequency and almost all 
laboratory test values, together with a gradual increase in 
body weight without nutritional supplementation. No 
longer in critical condition, she was discharged with 
valganciclovir (900 mg p.o. bid) for a further four weeks, 
followed by half dosage for another month. This led to the 
disappearance of ileal ulcerative lesions at the control 
endoscopy (Figure 1D), together with the absence of 
detectable HCMV DNA on both mucosa and peripheral 
blood. During the one-year follow-up period, the patient’s 
clinical parameters and laboratory tests normalised while 
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Figure 1: Radiological, endoscopic and histological features. Panel A: Coronal T1-weighted contrast enhanced magnetic 
resonance enterography showing ileal loops with thickened walls that are avidly enhanced after administration of contrast 
media. Both arrows indicate mesenteric “comb sign”, usually observed in the presence of an active inflammatory condition. 
Panel B: The presence of ulcerative lesions surrounded by a fibrinopurulent exudate and embedded in the oedematous and 
erythematous mucosa of an ileal loop is evident at the endoscopic examination. Panel C: Villous atrophy with focal hyperplastic 
regenerative changes of the surface epithelium, and active and heavy inflammatory infiltrate of the lamina propria 
characterised by lymphocytes, plasma cells and granulocytes are evident at histology. Haematoxylin and eosin staining 




The growing use of immunochemotherapy, especially for 
lymphoproliferative disorders, has led to an increase of 
opportunistic infections, including in non-transplanted 
haematological patients. However, very little evidence of 
HCMV infection in patients treated with bendamustine/ 
rituximab is available [7]. The case presented here of a life-
threatening HCMV enteropathy upon administration of this 
treatment not only underlines the need to consider this 
condition in differential diagnosis, but also serves to 
emphasise the importance of using the most appropriate 
analytical technique since in the gut mucosa immune-
histochemistry displays a poor sensitivity in comparison to 
qPCR [8]. More importantly, qPCR also allows the mucosal 
viral load to be quantified, which is crucial for correct 
patient management. Because the life cycle of the virus 
periodically switches from latency to activation to check the 
host’s immune system, the finding of positive cells by 
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immunohistochemistry does not give us any information 
about viral replication. Moreover, the value of 1.000 
copies/105 cells has already been identified as the cut-off 
limit to diagnosis of HCMV enterocolitis in inflammatory 
bowel disease patients receiving immunosuppressive 
therapy [8]. In this case we used the same value to make the 
decision to discontinue steroid therapy and to implement 
antiviral therapy, which rescued the patient from the life-
threatening condition. It is conceivable that reactivation of 
HCMV infection was dependent on the profound immune-
suppression due to rituximab therapy, and that localisation 
of end-organ disease in the distal ileum was due to the fact 
that this tract is one of the largest lymphoid organs in the 
body and particularly susceptible to immunosuppression. 
 
5. Conclusion 
Finally this case highlights the importance of an inter-
disciplinary approach and the clinical issue concerning 
the need to quantitatively evaluate viral load directly on 
tissue samples when a HCMV end organ disease is 
suspected, since peripheral blood levels may greatly 
underestimate those found in the  target organ. 
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